BRIEF-EMA Recommends Approval Of Imvanex For Prevention Of Monkeypox Disease

European Medicines Agency: * EMA: EMA RECOMMENDS APPROVAL OF IMVANEX FOR THE PREVENTION OF MONKEYPOX DISEASE: 22/07/2022

* EMA: HAS RECOMMENDED EXTENDING THE INDICATION OF THE SMALLPOX VACCINE IMVANEX TO INCLUDE PROTECTING ADULTS FROM MONKEYPOX DISEASE * EMA: IN ADDITION TO USE FOR PREVENTION OF MONKEYPOX, CHMP RECOMMENDED AUTHORISING IMVANEX TO PROTECT PEOPLE AGAINST DISEASE CAUSED BY VACCINIA VIRUS

* EMA: SAFETY PROFILE OF IMVANEX FAVOURABLE, WITH MILD TO MODERATE SIDE EFFECTS, AND CHMP CONCLUDED THAT MEDICINE'S BENEFITS ARE GREATER THAN RISKS Further company coverage: